Standard BioTools
LAB
86 hedge funds and large institutions have $70.2M invested in Standard BioTools in 2022 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 20 increasing their positions, 28 reducing their positions, and 40 closing their positions.
7.91% less ownership
Funds ownership: 64.72% → 56.8% (-7.9%)
21% less funds holding
Funds holding: 109 → 86 (-23)
29% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 28
48% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 40
61% less capital invested
Capital invested by funds: $180M → $70.2M (-$109M)
69% less call options, than puts
Call options by funds: $109K | Put options by funds: $352K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$4.92M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$2.81M |
| 3 |
Millennium Management
New York
|
+$1.63M |
| 4 |
E
Ergoteles
New York
|
+$862K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$515K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$10.3M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
-$5.87M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$3.52M |
| 4 |
State Street
Boston,
Massachusetts
|
-$2.98M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.63M |
LAB Hedge Fund Activity: Q2 2022 in Review
86 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q2 2022, worth a combined $70.2M — down 61% from $180M a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of LAB and 21 opened new positions — a net loss of 19 holders — while 28 trimmed existing stakes and 20 added.
The largest buyer was RA Capital Management, opening a new position worth an estimated $4.92M. The largest seller was BlackRock, cutting an estimated $10.3M.
- 86 institutional investors held Standard BioTools (LAB) as of Q2 2022, down from 109 in Q1 2022.
- Funds reported $70.2M of Standard BioTools stock for Q2 2022, down 61% quarter-over-quarter.
- 21 funds opened new Standard BioTools positions in Q2 2022 and 40 closed out, a net change of -19 holders.
- The largest Standard BioTools buyer in Q2 2022 was RA Capital Management, an estimated $4.92M added.
- The largest Standard BioTools seller in Q2 2022 was BlackRock, an estimated $10.3M sold.
Based on aggregated 13F filings for Q2 2022.